Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...

We are encouraged by the FDA’s Fast Track designation for BIIB080, which highlights the urgent need for innovative treatments targeting tau pathology in Alzheimer’s disease,” said Priya Singhal, M.D., ...

and gain approval in Europe or Asia, it could dramatically increase revenue. The market for Alzheimer's drugs is already estimated at $5.2 billion and could almost double by 2030. Biogen ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biogen is set to receive as much as $250 million in funding to develop a late-stage experimental lupus ...

Cambridge, Mass.-based Biogen had net income of $266.8 million, or $1.83 a share, for the quarter, up from $249.7 million, or $1.71 a share, a year ago. Adjusted for one-time items, EPS came to $3 ...

Biogen Inc. (NASDAQ: BIIB) has unveiled plans for its new global headquarters in Cambridge, located across the Charles River from Boston. The biotechnology company has selected Kendall Common, located ...

Biogen has announced plans to establish a new global headquarters and innovation hub in Cambridge, Mass., which will integrate its research and development, technical operations, and commercial teams ...

Biogen plans to relocate Cambridge-based employees to the new site in 2028 CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global ...